Pharma BD Deal Intelligence
An $8B bet on precision oncology's future. Lilly acquired Loxo to get Vitrakvi, the first tumor-agnostic TRK inhibitor, and selpercatinib (Retevmo), a best-in-class RET inhibitor. The deal also carried LOXO-305, later launched as Jaypirca (pirtobrutinib), the first non-covalent BTK inhibitor. The thesis was validated as Retevmo (FDA-approved 2020, tumor-agnostic 2024) and Jaypirca (2023; CLL/SLL indication expanded Dec 2025) both reached market, though Retevmo remains a modest seller (~$364M in 2024) given the rarity of RET-driven cancers.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Lilly's speedy $8 billion Loxo Oncology acquisition was 'not competitive,' according to analyst assessments, with the deal announced at J.P. Morgan Healthcare…
Retevmo (selpercatinib) generated worldwide sales of $364 million in 2024 ($456 million in 2023); not a major sales driver given the rarity of the RET…
U.S. FDA approves expanded indication for Lilly’s Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Eli Lilly acquired Loxo Oncology for approximately $8 billion ($235 per share) in an all-cash tender offer, gaining a precision oncology pipeline anchored by Vitrakvi (larotrectinib), the first tumor-agnostic TRK inhibitor approved by the FDA, and the RET inhibitor selpercatinib (LOXO-292).
50K US cases/yr · $15.0B Global BTK Inhibitor Market (2024)
BTK inhibitors have transformed B-cell malignancy treatment. Jaypirca (pirtobrutinib), acquired via Loxo, is a non-covalent (reversible) BTK inhibitor that works after covalent BTK inhibitor failure, addressing a critical unmet need in CLL and MCL.
Covalent BTKi: Imbruvica (AbbVie/J&J, declining), Calquence (AZ), Brukinsa (BeiGene, fastest growing). Non-covalent BTKi: Jaypirca (Lilly) addresses resistance to covalent agents. BTK degraders (NX-2127, NX-5948 from Nurix; ARQ 531 from Merck/ArQule) represent next wave. The BTK market exceeds $15B globally.
15K US cases/yr · $1.5B Global RET Inhibitor Market (2024)
RET alterations (fusions and mutations) drive ~1-2% of NSCLC, ~10-20% of thyroid cancers, and rare occurrences in other tumor types. Retevmo (selpercatinib) was the first selective RET inhibitor, achieving blockbuster status at $800M. RET testing is increasingly integrated into standard molecular profiling.
Retevmo (Lilly) dominates the RET market. Gavreto (pralsetinib, Roche/Blueprint) was the second approved selective RET inhibitor but was voluntarily withdrawn from US market. Next-gen agents target acquired resistance mutations (RET G810 solvent front mutations). The addressable patient population continues to grow with expanded testing.
3K US cases/yr · $800M Global NTRK Inhibitor Market (2024)
NTRK gene fusions occur in <1% of common cancers but up to 90% of rare tumors like secretory breast carcinoma and infantile fibrosarcoma. Vitrakvi (larotrectinib) was the first tumor-agnostic TRK inhibitor, representing precision oncology's paradigm of treating by molecular target rather than tumor site.
Vitrakvi (Lilly/Loxo) and Rozlytrek (Roche/entrectinib) are the two approved TRK inhibitors. Vitrakvi is more selective; Rozlytrek also covers ROS1. Next-gen TRK inhibitors (selitrectinib, repotrectinib) address acquired resistance. The small eligible population limits commercial potential but validates precision oncology.
Lilly acquired Loxo at $235/share, gaining Retevmo, Vitrakvi rights, and LOXO-305 precision oncology assets.
Change of control triggered Bayer option for exclusive Vitrakvi rights; Lilly receives royalties.
First therapy for RET-driven lung and thyroid cancers, validating Loxo acquisition thesis.
First and only RET inhibitor approved for all solid tumors with RET gene fusions.
Strategic Success in Precision Oncology. Assessment of Eli Lilly and Company's $8B acquisition of Loxo Oncology, Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Loxo Oncology, Inc. (this deal) | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2019 deals · Eli Lilly and Company deals · Oncology deals